Beta Bionics’ High‑Beta Gamble: When Upside Comes at a Heavy Downside Cost

Seven risk flags and a bull‑high‑vol regime signal persistent underperformance ahead

BBNX Beta Bionics, Inc.

In this report

01

Returns Overview

Period returns, alpha, cumulative performance, distributions

P. 2-3

→

02

Volatility Analysis

Annualized volatility, downside deviation, drawdowns

P. 4-5

→

03

Beta & Correlation

Trailing, upside, downside beta, systematic risk

P. 6-7

→

04

Risk-Adjusted Returns

Sharpe, Sortino, Calmar, Information, Treynor

P. 8-9

→

05

Market Regime Analysis

Bull/bear behavior, capture ratios

P. 10-11

→

06

Investment Highlights & Risk Summary

Executive summary, risk flags, rankings

P. 12-13

→

Returns Overview

Beta Bionics, Inc. (BBNX) — Return Performance

Beta Bionics (BBNX) exhibited highly volatile short‑term performance over the past year. The 1‑month total return was +14.6%, outpacing its XLV sector benchmark by 2.36 percentage points, while the 3‑month return surged to +38.62% versus a sector gain of +34.26%. However, momentum reversed sharply in the 6‑month window, with BBNX posting a -54.41% decline that was slightly deeper than the sector's -53.26% loss, and the 12‑month return settled at -4.6%, underperforming the sector by roughly 14.5 points. The absence of data beyond one year precludes assessment of longer‑term trends.

Period Returns vs S&P 500 & XLV

Monthly Returns Heatmap

BBNX

In the ultra‑short term (1–3 months), BBNX generated positive alpha relative to the healthcare sector, delivering 2.36% and 4.36% excess returns respectively. This outperformance dissipated in the medium horizon, as the 6‑month period showed a marginally worse decline than the benchmark, indicating heightened downside risk. The year‑to‑date result suggests the stock has not sustained its early gains, highlighting a divergence between short‑term upside potential and longer‑term volatility.

Returns Overview

Beta Bionics, Inc. (BBNX) — Return Charts

Volatility Analysis

Beta Bionics, Inc. (BBNX) — Volatility Profile

Beta Bionics exhibits an annualized volatility of 87.17%, which is nearly five times higher than the S&P 500's 17.78% benchmark. This extreme price swing reflects a highly speculative equity profile, driven by low liquidity and the binary nature of clinical‑stage biotech outcomes. Downside risk measures reinforce this view: a downside deviation of 62.15% signals that negative returns dominate the volatility spectrum, while a max drawdown of -72.3% over a three‑month window underscores the potential for rapid capital erosion without any sign of recovery to date.

Volatility Metrics

BBNX

The trailing 60‑day volatility (84.1%) and 252‑day volatility (81.57%) both sit above the long‑term annualized level of 87.17%, indicating that recent market movements have been slightly less extreme than the historical average but still far exceed broader market norms. The max drawdown, recorded from the January 8, 2026 peak to the April 10, 2026 trough, represents a 72.3% loss and persisted for roughly three months with no recovery, highlighting pronounced downside exposure. Investors should view this equity as having a high upside capture potential only if breakthrough clinical data materialize; otherwise, the risk of further steep declines remains significant.

Annualized volatility is 87.17%, about 4.9× the S&P 500's level.
Downside deviation of 62.15% indicates that most of the volatility stems from negative moves.
Maximum drawdown of -72.3% occurred over a three‑month period with no subsequent recovery.
Both 60‑day (84.1%) and 252‑day (81.57%) volatilities exceed the long‑term average, confirming sustained high risk.
The equity's risk profile is dominated by speculative biotech dynamics rather than broader market factors.

Positive Characteristics
Trailing volatility has marginally moderated relative to its peak annualized level, suggesting a slight easing of price swings.
High volatility can generate substantial upside if the company achieves pivotal regulatory or commercial milestones.

Volatility Analysis

Beta Bionics, Inc. (BBNX) — Volatility & Drawdown Charts

Beta & Correlation

Beta Bionics, Inc. (BBNX) — Beta Profile

Beta Bionics, Inc. (BBNX) exhibits a trailing market beta of 1.747, placing it firmly in the aggressive category (>1.2). This indicates that the stock tends to move 74.7% more than the S&P 500 on average, reflecting heightened sensitivity to broad equity market swings. The upside beta of 1.573 versus downside beta of 1.867 reveals a pronounced asymmetry: the share is more reactive to market declines than to advances, a characteristic that amplifies downside risk for investors during bearish periods. The low R‑squared of 0.124 (12.4% variance explained by the market) and correlation of 0.353 suggest that only a modest portion of BBNX’s price movements are driven by overall market dynamics; the majority is idiosyncratic. Systematic risk accounts for just 12.4% of total variance, while idiosyncratic risk dominates at 87.6%, underscoring limited diversification benefit from holding this stock alongside broader market exposure. Compared with its healthcare sector benchmark (XLV), BBNX’s sector beta of 1.582 and sector correlation of 0.307 indicate that the company is also more volatile than its peer group, but sector factors explain only 9.4% of price variance, confirming that most risk stems from company‑specific drivers.

Beta & Correlation Metrics

BBNX

The trailing market beta of 1.747 signals aggressive exposure to equity market movements, meaning a 1% rise (or fall) in the S&P 500 translates into an approximate 1.75% move in BBNX. The asymmetric upside/downside betas—1.573 versus 1.867—highlight that downside risk is about 18% higher than upside, which is critical for risk‑averse investors who prioritize capital preservation during market corrections. With a sector beta of 1.582, the stock also outpaces its healthcare peers, but the modest sector R² (9.4%) confirms that most of this volatility originates from firm‑specific factors rather than sector trends.

BBNX’s market beta of 1.747 classifies it as an aggressive stock with amplified exposure to overall equity market moves.
Downside beta (1.867) exceeds upside beta (1.573), indicating greater sensitivity to market declines than rallies.
R‑squared of 0.124 shows that only 12.4% of price variance is explained by the S&P 500, leaving 87.6% driven by idiosyncratic factors.
Systematic risk comprises just 12.4% of total variance, while idiosyncratic risk dominates at 87.6%, limiting diversification benefits.
Sector beta (1.582) exceeds the market beta, but sector R² (9.4%) is lower than market R², confirming that company‑specific drivers outweigh sector influences.

Positive Characteristics
High upside beta of 1.573 suggests the stock can capture a sizable portion of market rallies.
Sector beta above 1 indicates potential for outperformance relative to healthcare peers during sector uptrends.
Low correlation with both market (0.353) and sector (0.307) provides some diversification benefit in a multi‑asset portfolio.

Beta & Correlation

Beta Bionics, Inc. (BBNX) — Rolling Beta

Positive Notes

High upside beta of 1.573 suggests the stock can capture a sizable portion of market rallies.

Sector beta above 1 indicates potential for outperformance relative to healthcare peers during sector uptrends.

Low correlation with both market (0.353) and sector (0.307) provides some diversification benefit in a multi‑asset portfolio.

Risk-Adjusted Returns

Beta Bionics, Inc. (BBNX) — Risk-Adjusted Performance

Beta Bionics, Inc. (BBNX) exhibits uniformly negative risk-adjusted performance metrics, indicating that over the measurement period the stock has underperformed the risk‑free rate on a risk‑adjusted basis. The Sharpe ratio of -0.051 and Treynor ratio of -2.523 both signal that the total and systematic returns are insufficient to compensate for volatility and market exposure, respectively. Downside‑focused measures such as the Sortino (-0.071) and Calmar (-0.011) ratios remain negative, underscoring that not only has the stock lagged risk‑free returns, but it also suffered pronounced drawdowns relative to its best historical peak.

Risk-free rate: 3.63% (Fed Funds Rate)

Risk-Adjusted Metrics

BBNX

BBNX ranks at the bottom of any peer set for overall risk-adjusted performance, as all five metrics are negative. The Sharpe ratio is marginally less adverse than the Sortino ratio, suggesting that downside volatility slightly exceeds total volatility, but both ratios remain below zero, confirming an unfavorable risk‑adjusted return profile. The Calmar ratio of -0.011 reflects a severe maximum drawdown relative to any positive returns, implying that investors would have endured substantial capital erosion during market downturns. An Information Ratio of -0.205 further indicates that the stock has not generated consistent alpha beyond its benchmark, reinforcing concerns about active management effectiveness.

All risk-adjusted metrics for BBNX are negative, indicating underperformance versus the 3.63% risk‑free rate.
The Sharpe (-0.051) is slightly less negative than the Sortino (-0.071), showing that downside volatility contributes more to the poor performance than total volatility.
A Calmar ratio of -0.011 signals a severe drawdown relative to any positive return, highlighting high tail‑risk exposure.
The Information Ratio of -0.205 suggests inconsistent or negative alpha generation compared with a typical benchmark.

Positive Characteristics
None identified; the current risk-adjusted metrics provide no evidence of upside risk‑adjusted strength.

Risk-Adjusted Returns

Beta Bionics, Inc. (BBNX) — Rolling Sharpe & Sortino

Positive Notes

None identified; the current risk-adjusted metrics provide no evidence of upside risk‑adjusted strength.

Market Regime Analysis

Beta Bionics, Inc. (BBNX) — Regime Behavior

Beta Bionics (BBNX) exhibits pronounced sensitivity to market conditions, delivering modest gains in calm uptrends but exploding higher during volatile bull markets. In a Bull‑LowVol environment the stock posted an average monthly return of 1.29%, reflecting limited upside when broader equity sentiment is subdued. Conversely, the Bull‑HighVol regime produced an impressive 13.74% average gain, indicating that the company’s equity price benefits strongly from heightened market turbulence while the S&P remains above its 50‑day SMA. In bear markets the stock’s performance deteriorates sharply; no data exist for orderly declines (Bear‑LowVol), but during Bear‑HighVol periods the average return plunged to –20.17%, underscoring significant downside risk when volatility spikes amid a falling market. The current Bull‑HighVol regime therefore favors BBNX, aligning with its historical upside capture of 240.7% and exposing investors to heightened downside capture at 488.4%. While the capture ratio of 0.49 signals that losses outweigh gains in adverse conditions, the prevailing environment should support strong short‑term performance.

Current Market Regime: Bull-HighVol

Bull-LowVol = calm uptrend • Bull-HighVol = volatile uptrend • Bear-LowVol = orderly decline • Bear-HighVol = crisis

Regime Returns & Capture Ratios

BBNX

In Bull‑LowVol periods BBNX delivers modest upside (1.29% avg) as investors seek stable growth stocks; its high upside capture suggests it still outperforms the market, but the muted return reflects limited momentum. During Bull‑HighVol cycles the stock’s average gain jumps to 13.74%, driven by a strong upside capture of 240.7%, meaning it generates more than double the S&P’s returns when markets rise sharply amid volatility. In Bear‑HighVol regimes the equity suffers severe drawdowns (–20.17% avg) with a downside capture of 488.4%, indicating that for every 1% loss in the market, BBNX loses nearly five percent, making it highly defensive‑averse. The absence of data for Bear‑LowVol suggests limited historical exposure to orderly declines, but given its high downside capture, the stock would likely underperform even in calmer bear markets.

Market Regime Analysis

Beta Bionics, Inc. (BBNX) — Regime & Capture Charts

Regime Timeline

BBNX’s upside capture (240.7%) far exceeds its downside capture (488.4%), resulting in a capture ratio of 0.49, which signals greater vulnerability to market drops than to gains.
The stock thrives in Bull‑HighVol environments, delivering an average monthly return of 13.74%, whereas it incurs steep losses (-20.17%) during Bear‑HighVol periods.
Defensive characteristics are absent; BBNX does not perform relatively well in bear regimes and is thus not a defensive name.

Positive Characteristics
Current Bull‑HighVol regime aligns with the company’s historical strength, supporting potential upside momentum.
High upside capture indicates strong relative performance when equities rally sharply, offering asymmetric upside potential in volatile bull markets.

Investment Highlights & Risk Summary

Beta Bionics, Inc. (BBNX) — Summary & Implications

Beta Bionics (BBNX) operates in the healthcare sector but has delivered a negative 1‑year return of -4.6% and an alpha of -23.6% versus the S&P 500, indicating substantial underperformance. The stock’s risk profile is aggressive: a beta of 1.747 amplifies market moves, annualized volatility stands at 87.2%, and the maximum drawdown over the past year reached -72.3%. Risk‑adjusted performance is weak, with a Sharpe ratio of -0.051 and a Sortino ratio of -0.071, both below zero, meaning returns have not compensated for risk or downside volatility. While upside capture is high at 240.7%, the downside capture of 488.4% reveals that losses are magnified far more than gains, creating an unfavorable asymmetry for investors.

Summary Dashboard

Investment Highlights

Upside capture of 240.7% shows the stock participates strongly in market rallies, potentially delivering outsized gains if broader equity markets surge.
Beta of 1.747 provides leveraged exposure to market movements, which can be attractive for risk‑seeking investors seeking amplified upside during bullish periods.
Operating within the healthcare sector (XLV) offers long‑term thematic growth potential from demographic trends and medical innovation, despite current underperformance.

Risk-Return Rankings

BBNX HIGH

High beta and volatility combine with deep drawdowns to produce a risk‑heavy profile that outweighs modest upside capture.

Strength: Strong upside capture (240.7%) indicating potential for large gains in rising markets.

Concern: Negative Sharpe (-0.051) and extreme downside capture (488.4%) signal poor risk‑adjusted returns and amplified losses.

Key Takeaways

The stock’s high beta (1.747) and volatility (87.2% annualized) mean price swings will be far larger than the market average.
Negative risk‑adjusted metrics (Sharpe -0.051, Sortino -0.071) indicate that returns have not compensated for the level of risk taken.
A maximum drawdown of -72.3% highlights a history of severe capital erosion, which could be difficult to recover from without strong market rebounds.
Upside capture is impressive, but downside capture at 488.4% creates an asymmetric risk profile that favors losses over gains.

PORTFOLIO IMPLICATIONS

Given its high beta and volatility, BBNX would suit a small allocation within a growth‑oriented or thematic healthcare portfolio where investors are comfortable with large swings and seek potential upside in strong market rallies. The pronounced downside capture suggests it should be paired with lower‑beta, defensive holdings to temper overall portfolio risk and improve the aggregate Sharpe ratio. Investors should monitor sector dynamics and macro trends closely, as any prolonged market weakness could exacerbate losses on this position.

BBNX

Related Reports

Visit finexus.net/reports for more reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.